References
- Blanke C. D. Role of COX-2 inhibitors in cancer therapy. Cancer Investig. 2002
- Zacharski L. R. Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy. Haemostasis 1986; 16: 300–320, [PUBMED], [INFOTRIEVE]
- Chahinian A. P., Propert K. J., Ware J. H., Zimmer B., Perry M. C., Hirsh V., Skarin A., Kopel S., Comis R. L., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol. 1989; 7: 993–1002, [PUBMED], [INFOTRIEVE]
- Zacharski L. R., Henderson W. G., Rickles F. R., Forman W. B., Cornell C. J., Jr., Forcier R. J., Edwards R. L., Headley E., Kim S. H., O'Donnell J. F., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 2046–2052, [PUBMED], [INFOTRIEVE]
- Coffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235–242, [CROSSREF]
- Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344: 783–792, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]